Jialing Liu1,2, Yi Li1, Lingna Lyu1,3, Liang Xiao1,4, Aliza A Memon1, Xin Yu5, Arvin Halim1, Shivani Patel6, Abdikheyre Osman7, Wenqing Yin6, Jie Jiang8,9, Said Naini1, Kenneth Lim10, Aifeng Zhang1, Jonathan D Williams11, Ruth Koester11, Kevin Z Qi12, Quynh-Anh Fucci1, Lai Ding13, Steven Chang14, Ankit Patel1, Yutaro Mori1, Advika Chaudhari1, Aaron Bao15, Jia Liu16, Tzong-Shi Lu1, Andrew Siedlecki17. 1. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 2. Nephrology, Department of Medicine, Guangzhou University of Chinese Medicine, The Second Affiliated Hospital of Chinese Medicine, Guangzhou, China. 3. Department of Molecular Biology, Beijing Chest Hospital, Capital Medical University, Beijing, China. 4. Department of Surgery and Oncology, Shenzhen Second People's Hospital/the First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China. 5. Blood Transfusion Research Institute, Wuxi Red Cross Blood Center, Wuxi, Jiangsu, China. 6. Division of Nephrology, Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts. 7. Harvard College, Cambridge, Massachusetts. 8. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. 9. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts. 10. Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana. 11. DNA Identification Testing Division, Laboratory Corporation of America Holdings, Burlington, North Carolina. 12. Boston College, Boston, Massachusetts. 13. Program for Interdisciplinary Neuroscience, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 14. Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 15. Washington University in St. Louis, St. Louis, Missouri. 16. Shenzhen Jiake Biotechnology, Shenzhen, China. 17. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts asiedlecki@bwh.harvard.edu.
Abstract
BACKGROUND: Endothelial cell injury is a common nidus of renal injury in patients and consistent with the high prevalence of AKI reported during the coronavirus disease 2019 pandemic. This cell type expresses integrin α5 (ITGA5), which is essential to the Tie2 signaling pathway. The microRNA miR-218-5p is upregulated in endothelial progenitor cells (EPCs) after hypoxia, but microRNA regulation of Tie2 in the EPC lineage is unclear. METHODS: We isolated human kidney-derived EPCs (hkEPCs) and surveyed microRNA target transcripts. A preclinical model of ischemic kidney injury was used to evaluate the effect of hkEPCs on capillary repair. We used a genetic knockout model to evaluate the effect of deleting endogenous expression of miR-218 specifically in angioblasts. RESULTS: After ischemic in vitro preconditioning, miR-218-5p was elevated in hkEPCs. We found miR-218-5p bound to ITGA5 mRNA transcript and decreased ITGA5 protein expression. Phosphorylation of 42/44 MAPK decreased by 73.6% in hkEPCs treated with miR-218-5p. Cells supplemented with miR-218-5p downregulated ITGA5 synthesis and decreased 42/44 MAPK phosphorylation. In a CD309-Cre/miR-218-2-LoxP mammalian model (a conditional knockout mouse model designed to delete pre-miR-218-2 exclusively in CD309+ cells), homozygotes at e18.5 contained avascular glomeruli, whereas heterozygote adults showed susceptibility to kidney injury. Isolated EPCs from the mouse kidney contained high amounts of ITGA5 and showed decreased migratory capacity in three-dimensional cell culture. CONCLUSIONS: These results demonstrate the critical regulatory role of miR-218-5p in kidney EPC migration, a finding that may inform efforts to treat microvascular kidney injury via therapeutic cell delivery.
BACKGROUND: Endothelial cell injury is a common nidus of renal injury in patients and consistent with the high prevalence of AKI reported during the coronavirus disease 2019 pandemic. This cell type expresses integrin α5 (ITGA5), which is essential to the Tie2 signaling pathway. The microRNA miR-218-5p is upregulated in endothelial progenitor cells (EPCs) after hypoxia, but microRNA regulation of Tie2 in the EPC lineage is unclear. METHODS: We isolated human kidney-derived EPCs (hkEPCs) and surveyed microRNA target transcripts. A preclinical model of ischemic kidney injury was used to evaluate the effect of hkEPCs on capillary repair. We used a genetic knockout model to evaluate the effect of deleting endogenous expression of miR-218 specifically in angioblasts. RESULTS: After ischemic in vitro preconditioning, miR-218-5p was elevated in hkEPCs. We found miR-218-5p bound to ITGA5 mRNA transcript and decreased ITGA5 protein expression. Phosphorylation of 42/44 MAPK decreased by 73.6% in hkEPCs treated with miR-218-5p. Cells supplemented with miR-218-5p downregulated ITGA5 synthesis and decreased 42/44 MAPK phosphorylation. In a CD309-Cre/miR-218-2-LoxP mammalian model (a conditional knockout mouse model designed to delete pre-miR-218-2 exclusively in CD309+ cells), homozygotes at e18.5 contained avascular glomeruli, whereas heterozygote adults showed susceptibility to kidney injury. Isolated EPCs from the mouse kidney contained high amounts of ITGA5 and showed decreased migratory capacity in three-dimensional cell culture. CONCLUSIONS: These results demonstrate the critical regulatory role of miR-218-5p in kidney EPC migration, a finding that may inform efforts to treat microvascular kidney injury via therapeutic cell delivery.
Authors: Nikos Werner; Sonja Kosiol; Tobias Schiegl; Patrick Ahlers; Katrin Walenta; Andreas Link; Michael Böhm; Georg Nickenig Journal: N Engl J Med Date: 2005-09-08 Impact factor: 91.245
Authors: Eric M Small; Lillian B Sutherland; Kartik N Rajagopalan; Shusheng Wang; Eric N Olson Journal: Circ Res Date: 2010-10-14 Impact factor: 17.367
Authors: Paul Pang; Molly Abbott; Steven L Chang; Malyun Abdi; Nikita Chauhan; Murti Mistri; Joshua Ghofrani; Quynh-Anh Fucci; Colleen Walker; Corey Leonardi; Samuel Grady; Arvin Halim; Ryan Hoffman; Tzongshi Lu; Huixia Cao; Stefan G Tullius; Sayeed Malek; Sanjaya Kumar; Graeme Steele; Adam Kibel; Benjamin S Freedman; Sushrut S Waikar; Andrew M Siedlecki Journal: Kidney Int Date: 2016-09-29 Impact factor: 10.612
Authors: Michael Rudnicki; Paul Perco; Julia Enrich; Susanne Eder; Dorothea Heininger; Andreas Bernthaler; Martin Wiesinger; Rita Sarközi; Susie-Jane Noppert; Herbert Schramek; Bernd Mayer; Rainer Oberbauer; Gert Mayer Journal: Lab Invest Date: 2009-01-12 Impact factor: 5.662
Authors: Paul Pang; Xiaohua Jin; Brandon M Proctor; Michelle Farley; Nilay Roy; Matthew S Chin; Ulrich H von Andrian; Elisabeth Vollmann; Mario Perro; Ryan J Hoffman; Joseph Chung; Nikita Chauhan; Murti Mistri; Anthony J Muslin; Joseph V Bonventre; Andrew M Siedlecki Journal: Kidney Int Date: 2014-12-03 Impact factor: 10.612
Authors: Jamie S Hirsch; Jia H Ng; Daniel W Ross; Purva Sharma; Hitesh H Shah; Richard L Barnett; Azzour D Hazzan; Steven Fishbane; Kenar D Jhaveri Journal: Kidney Int Date: 2020-05-16 Impact factor: 10.612